Cargando…
Quality assessment and its impact on clinical performance of a biosimilar erythropoietin: A simulated case study
The case study described in this paper was developed for the purpose of training for a better understanding of principles relating especially to a comprehensive evaluation of multiple quality attributes as outlined in the WHO guidelines on evaluation of similar biotherapeutic products. It is also to...
Autores principales: | Thorpe, Robin, Grampp, Gustavo, Kang, Hye-Na, Knezevic, Ivana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academic Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863428/ https://www.ncbi.nlm.nih.gov/pubmed/31668854 http://dx.doi.org/10.1016/j.biologicals.2019.10.006 |
Ejemplares similares
-
The regulatory landscape of biosimilars: WHO efforts and progress made from 2009 to 2019
por: Kang, Hye-Na, et al.
Publicado: (2020) -
Regulatory evaluation of biosimilars throughout their product life-cycle
por: Kang, Hye-Na, et al.
Publicado: (2018) -
Pharmacovigilance Considerations for Biosimilars in the USA
por: Grampp, Gustavo, et al.
Publicado: (2015) -
The Diversity of Biosimilar Design and Development: Implications for Policies and Stakeholders
por: Grampp, Gustavo, et al.
Publicado: (2015) -
Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience
por: Kurki, Pekka, et al.
Publicado: (2022)